Staidson BioPharm: Xiangtang Group reduced its holdings by 3.3607 million shares of the company

Staidson BioPharm announced that its shareholder holding more than 5% of shares, Xiangtang Group Co., Ltd., reduced its holdings by 3.3607 million shares of Staidson BioPharm through centralized bidding on the stock exchange on September 8, 2025, and September 9, 2025, accounting for 0.70% of the total voting shares of the company. Currently, the combined shareholding ratio of Xiangtang Group and its concerted parties has decreased from 7.69% to 6.99%